Asset profile
Abemaciclib · Verzenio
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Abemaciclib (Verzenio): this drug | Approved | Small molecule | CDK4 and CDK6 | ||
| Palbociclib (Ibrance) | Approved | Small molecule | CDK4 and CDK6 | ||
| Ribociclib | Approved | Small molecule | CDK4 and CDK6 | ||
| BPI-16350 | Phase 3 | Small molecule | CDK4 and CDK6 | ||
| Dalpiciclib | Phase 3 | Small molecule | CDK4 and CDK6 | ||
| BPI-1178 | Phase 1/2 | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) |
…and 50 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(90 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (7)
November 2026 (2)
Phase 1Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian CarcinomaRecruiting
Est. primary completion 2026-11-01 · NCT04633239 · CT.gov ↗
What to watch
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2026-11-25 · NCT05159245 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05307705 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05386108 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-01 · NCT05305924 · CT.gov ↗
What to watch
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04393285 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
2027 (41)
January 2027 (5)
Phase 1Myelofibrosis Due to and Following Polycythemia VeraRecruiting
Est. primary completion 2027-01 · NCT05714072 · CT.gov ↗
What to watch
Phase 2Intracranial Meningioma, Recurrent Meningioma, NF2 Gene MutationRecruiting
Est. primary completion 2027-01-01 · NCT02523014 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-10 · NCT06207734 · CT.gov ↗
What to watch
Phase 1/2Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma …Recruiting
Est. primary completion 2027-01-31 · NCT06498648 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1/2Metastatic Renal Cell Carcinoma, Translocation Renal Cell CarcinomaRecruiting
Est. primary completion 2027-02 · NCT06835972 · CT.gov ↗
What to watch
Phase 2GliomaActive not recruiting
Est. primary completion 2027-02 · NCT06413706 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-02-25 · NCT06341621 · CT.gov ↗
What to watch
March 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2027-03-20 · NCT06594679 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-03-24 · NCT05548127 · CT.gov ↗
What to watch
Phase 1/2Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer …Recruiting
Est. primary completion 2027-03-31 · NCT06810544 · CT.gov ↗
What to watch
April 2027 (6)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT05696626 · CT.gov ↗
What to watch
Phase 1Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma …Recruiting
Est. primary completion 2027-04-01 · NCT06654037 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT05501704 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-15 · NCT04614194 · CT.gov ↗
What to watch
Phase 2Liver Metastases From Colorectal Cancer (mCRC)Enrolling by invitation
Est. primary completion 2027-04-30 · NCT07441369 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2Neoplasms, Child, AdolescentRecruiting
Est. primary completion 2027-05 · NCT05999994 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-21 · NCT04305834 · CT.gov ↗
What to watch
Phase 1/2Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2027-05-31 · NCT05113537 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06 · NCT05095207 · CT.gov ↗
What to watch
Phase 1/2Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT05774899 · CT.gov ↗
What to watch
Phase 2Chondrosarcoma, Osteosarcoma, Soft Tissue SarcomaRecruiting
Est. primary completion 2027-06-01 · NCT04040205 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-07 · NCT05372640 · CT.gov ↗
What to watch
July 2027 (5)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT05735080 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT04923542 · CT.gov ↗
What to watch
Phase 2Brain TumorActive not recruiting
Est. primary completion 2027-07 · NCT03220646 · CT.gov ↗
What to watch
Phase 2Sarcoma, Dedifferentiated LiposarcomaActive not recruiting
Est. primary completion 2027-07 · NCT02846987 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT04469764 · CT.gov ↗
What to watch
August 2027 (2)
September 2027 (3)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Endometrial Cancer, Recurrent Endometrial Cancer, TP53Recruiting
Est. primary completion 2027-09-01 · NCT06366347 · CT.gov ↗
What to watch
Phase 2Malignant Neoplasms of Female Genital OrgansActive not recruiting
Est. primary completion 2027-09-30 · NCT03531645 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗
What to watch
December 2027 (5)
Phase 2Triple Negative Breast NeoplasmsRecruiting
Est. primary completion 2027-12 · NCT06365788 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT04523857 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07599137 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05608252 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
2028 (23)
January 2028 (2)
February 2028 (4)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02 · NCT05573126 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2028-02-01 · NCT02977780 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial TumorRecruiting
Est. primary completion 2028-02-17 · NCT06813079 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1/2Kaposi SarcomaRecruiting
Est. primary completion 2028-03-01 · NCT04941274 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04-20 · NCT06065748 · CT.gov ↗
What to watch
May 2028 (2)
June 2028 (2)
July 2028 (2)
August 2028 (2)
September 2028 (1)
October 2028 (1)
Phase 2Endometrial CancerRecruiting
Est. primary completion 2028-10-01 · NCT07209449 · CT.gov ↗
What to watch
November 2028 (2)
December 2028 (3)
Phase 1/2Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma …Active not recruiting
Est. primary completion 2028-12-31 · NCT04616183 · CT.gov ↗
What to watch
Phase 1/2Neurofibromatosis 1Recruiting
Est. primary completion 2028-12-31 · NCT04750928 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05524584 · CT.gov ↗
What to watch
2029 (8)
April 2029 (3)
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-04 · NCT05362760 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-04-01 · NCT07410559 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-04-30 · NCT07428018 · CT.gov ↗
What to watch
May 2029 (2)
June 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-06-30 · NCT07605728 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-09 · NCT07490509 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
2030 (8)
March 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-03-04 · NCT05952557 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-04-30 · NCT07191717 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
October 2030 (2)
November 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-11 · NCT06169371 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (2)
June 2031 (1)
Phase 2Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer …Recruiting
Est. primary completion 2031-06-02 · NCT07340541 · CT.gov ↗
What to watch
October 2031 (1)
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-10 · NCT07406594 · CT.gov ↗
What to watch
2034 (1)
February 2034 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2034-02-06 · NCT07190443 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.